New Clinical Results from APOLLO Phase 3 Study of Patisiran at ISA

New Clinical Results from APOLLO Phase 3 Study of Patisiran at ISA

We presented additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, at the 16th International Symposium on Amyloidosis (ISA), held March 26-29, 2018 in Kumamoto, Japan.

Read our press release

Kristen et al. – “APOLLO, a Phase 3 Study of Patisiran for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis: 18-Month Safety and Efficacy in Subgroup of Patients with Cardiac Involvement”

Coelho et al. – “Patisiran, an Investigational RNAi Therapeutic for Patients with Hereditary Transthyretin-Mediated Amyloidosis: Regional and Genotypic Subgroup Analyses from the APOLLO Study”

Schmidt et al. – “Impact of Hereditary Transthyretin-Mediated Amyloidosis on Use of Health Care Services: An Analysis of the APOLLO Study”

Polydefkis et al. – “Relationship Between Transthyretin Knockdown and Change in mNIS+7: Findings from the Patisiran Phase 2 Open-Label Extension and Phase 3 APOLLO Studies for Patients with Hereditary Transthyretin-Mediated Amyloidosis”

Gonzalez-Duarte et al. – “Changes in Neuropathy Stage in Patients with Hereditary Transthyretin-Mediated Amyloidosis Following Treatment with Patisiran, an Investigational RNAi Therapeutic: An Analysis from the Phase 3 APOLLO Study”

Suhr et al. – “Long-Term Use of Patisiran, an Investigational RNAi Therapeutic, in Patients with Hereditary Transthyretin-Mediated Amyloidosis: Baseline Demographics and Interim Data from Global Open Label Extension Study”

Gillmore et al. – “Home Infusion Administration of Patisiran, an Investigational RNAi Therapeutic in Patients with Hereditary Transthyretin-Mediated Amyloidosis: An Analysis of Safety and Adherence”

Berk et al. – “Impact of Hereditary Transthyretin-Mediated Amyloidosis on Daily Living and Work Productivity: Baseline Results from APOLLO”

Yamashita et al. – “Patisiran, an Investigational RNAi Therapeutic for Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis: Phase 3 APOLLO Study Sub-Analysis of Japanese Patients”

 

In addition, we presented new data from the Phase 1 study of ALN-TTRsc02, an investigational, subcutaneously administered RNAi therapeutic for the treatment of ATTR amyloidosis.

Vest et al. – “Phase 1 Study of ALN-TTRsc02, a Subcutaneously Administered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis”